Evaluating Different Immunotherapy Combinations
A platform clinical trial evaluates immunotherapy combinations with standard of care treatment for advanced pancreatic cancer.
A platform clinical trial evaluates immunotherapy combinations with standard of care treatment for advanced pancreatic cancer.
While immunotherapy and other targeted treatments involving monoclonal antibodies have been successful in other cancers, pancreatic cancer has been notoriously tough to target because of a lack of suitable cell surface targets to which the antibodies can bind. But a new target has been identified, and researchers are hopeful that an investigational drug that homes…
A clinical trial looks at whether molecular subtyping of tumors is effective in determining the best pancreatic cancer treatment.
Researcher Dr. Gehan Botrus looks at circulating tumor DNA for genetic information on a patient’s pancreatic cancer to personalize treatment.
Wayne Mullis credits his treatment team with choosing the best pancreatic cancer treatment for him and for helping him through treatment.
That’s the question researchers hoped to answer in a phase II double-blind trial comparing mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients. Results of the trial were presented at the 2021 ASCO GI Cancer Symposium. Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2, a vascular…
Dr. Allyson Ocean explains the concept behind a novel second-line treatment being tested for metatstatic pancreatic cancer.
Drs. Jennifer Knox and Elizabeth Jaffee lead the PASS-01 trial using biomarkers and other measures to choose individualized treatment.
Do you want to understand more about how your doctor chooses your treatments? Learn about the standard of care for pancreatic cancer.
Researchers are using IORT–intraoperative radiation therapy–to treat pancreatic cancer that cannot be surgically removed.